Skip to Content

Halberd Corp HALB

Morningstar Rating
$0.01 0.00 (1.25%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HALB is trading at a 61% discount.
Price
$0.01
Fair Value
$7.77
Uncertainty
Extreme
1-Star Price
$6.96
5-Star Price
$3.26
Economic Moat
Gvrkd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HALB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.000.01
Bid/Ask
$0.01 / $0.01
Market Cap
$221,493.00
Volume/Avg
171,636 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1,820.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
3

Valuation

Metric
HALB
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
1,820.00
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
HALB
Quick Ratio
0.01
Current Ratio
0.01
Interest Coverage
−65.02
Quick Ratio
HALB

Profitability

Metric
HALB
Return on Assets (Normalized)
−3,091.66%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
HALB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGjswdtxsxQwnr$559.8 Bil
VRTX
Vertex Pharmaceuticals IncJshpkgkcQfydmv$102.5 Bil
REGN
Regeneron Pharmaceuticals IncYllydzzfJxbbclv$98.6 Bil
MRNA
Moderna IncWcwcpyzPfws$41.0 Bil
ARGX
argenx SE ADRPftsbpywRcj$22.6 Bil
BNTX
BioNTech SE ADRMqycqlxtZkjpl$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncXpmwzvlqsZnfthlb$18.8 Bil
BMRN
Biomarin Pharmaceutical IncBplztpqjTbttpk$17.4 Bil
RPRX
Royalty Pharma PLC Class AWlgqsccsgVjskxgd$12.6 Bil
INCY
Incyte CorpSvxcrvcxDhldpx$12.0 Bil

Sponsor Center